JNJ logo
Johnson & Johnson
JNJ
246.31 (0.18%) 0.44
Health Care
Pharmaceuticals
Johnson & Johnson together with its subsidiaries engages in the research and development manufacture and sale of a range of products in the healthcare field worldwide. It operates in two segments Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas such as oncology immunology neuroscience pulmonary hypertension infectious diseases and cardiovascular and metabolism distributed through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery orthopedic cardiovascular and vision fields distributed through wholesalers hospitals and retailers and used in the professional fields by physicians nurses hospitals eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction trauma spine sports related injuries and others as well as open laparoscopic and robotic surgical procedures; instrumentation energy devices stapling systems wound closure biosurgery products and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick New Jersey.

Quality Checklist 6/8

5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $593.58(B)
EV: $620.79(B)
Total Equity: $81.54(B)
Earnings date: Apr-14-2026
P/E: 22.13
Forward P/E: 21.36
P/FCF: 30.11
P/S: 6.29
P/B: 7.27
EPS: $11.1
EPS (fwd): $11.5
FCF/share: $8.2
Revenue/share: $39.1
Book value/share: $33.9
ROIC: 21.7%
ROA: 13.5%
ROE: 33.6%
Debt/Equity: 0.60
Current Ratio: 1.00
Gross margin: 68.1%
Operating margin: 26.2%
Net margin: 28.5%
Dividend/share: $5.1
Div. yield: 2.09%

Growth Estimates

Revenue

CAGR: 5.8%
FY+1FY+2FY+3FY+4FY+5
FY+1$100.59(B)
FY+2(+5.3%)$105.94(B)
FY+3(+6.3%)$112.64(B)
FY+4(+5.8%)$119.20(B)
FY+5(+5.9%)$126.23(B)

Net Income

CAGR: 8.4%
FY+1FY+2FY+3FY+4FY+5
FY+1$28.09(B)
FY+2(+8.3%)$30.44(B)
FY+3(+8.0%)$32.86(B)
FY+4(+8.2%)$35.57(B)
FY+5(+9.1%)$38.81(B)

EPS

CAGR: 9.3%
FY+1FY+2FY+3FY+4FY+5
FY+1$11.53
FY+2(+8.8%)$12.54
FY+3(+8.8%)$13.64
FY+4(+9.4%)$14.92
FY+5(+10.1%)$16.43

FCF per share

CAGR: 9.5%
FY+1FY+2FY+3FY+4FY+5
FY+1$10.51
FY+2(+3.5%)$10.88
FY+3(+13.2%)$12.32
FY+4(+14.0%)$14.05
FY+5(+7.6%)$15.12